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MDS. Reduced toxicity conditioning with ﬂudarabine and
treosulfan (FT) is a dose intensive regimen with enhanced
anti leukemia effect and acceptable toxicity. However,
relapse after SCT remains the main obstacle to cure. Natural
killer (NK) cell alloreactivity has documented role in
reducing relapse after haploidentical SCT in AML but its role
in HLA matched SCT is more controversial. The missing
ligand theory suggests that missing KIR ligands in the
recipient may drive donor NK alloreactivity in the absence of
HLA mismatch. There is no data on NK cell role in treosulfan
based conditioning. Here we analyzed the prognostic factors
for relapse and overall survival (OS) in 203 pts with AML
(n¼129, 29 secondary) and MDS (n¼74) given SCT from
matched sibling (n¼97) or matched unrelated donors
(n¼106) using FT conditioning. Median age was 58 years
(21e76). Disease status was CR1 (n¼65), CR2/3 (n¼24), no CR
(n¼44) or previously untreated MDS (n¼70). 67% expressed
at least one Bw4 antigen, 81% expressed C group 1 alleles and
66% C group 2 alleles. With median follow-up of 48 months
(6-108) 86 pts are alive, 66 died of relapse and 51 of non-
relapse causes (NRM). 5-year OS and leukemia-free survival
(LFS) rates were 39% and 36%, respectively. 5-year cumula-
tive incidence of relapse and NRM was 38% and 27%,
respectively. The most signiﬁcant predictor of relapse was
disease status at SCT. 5-year relapse rates were 33% in CR/
untreated MDS and 55% in refractory disease (p¼0.001). Pts
expressing HLA C group 1alleles had a relapse rate of 45%
compared to 26% in pts with missing group 1 ligands
(p¼0.03). Missing HLA C group 2 or Bw4 ligands had no effect
on relapse. Multivariate analysis identiﬁed no CR at SCT (HR
3.6, p¼0.001), missing HLA C group 1 ligand (HR 2.6, p¼0.03),
sibling donor (HR 1.8, p¼0.04), poor cytogenetics (HR 1.7,
p¼0.05) and female donor to male recipient (HR 0.5, p¼0.06)
as independent factors predicting relapse. The reduced
relapse rate associated with missing HLA C group 1 ligand
was more pronounced in pts with MDS/ secondary AML, 39%
Vs 7%, respectively (p¼0.02) and in pts in untreated disease
or no CR, 46% Vs. 8%, respectively (p¼0.02). Missing HLA li-
gands were not associated with GVHD or NRM. LFS was 46%
in pts with missing HLA C group1 ligand compared to 30% in
pts expressing the ligand (p¼0.07). Multivariate analysis
identiﬁed SCT not in CR (HR 2.8, p¼0.0007), SCT comorbidity
score > 2 (HR 1.5, p¼0.06) and missing HLA C group 1 ligand
(HR 1.9, p¼0.02) as independent predicting factor for LFS. In
conclusion, missing HLA C group 1 ligand in SCT recipients
with AML/ MDSmay be associated with reduced relapse risk,
similar NRM and improved LFS possibly due to enhanced NK
alloreactivity. These observations merit further study in
larger cohorts and in pts given other conditioning regimens
to elucidate the potential role of treosulfan conditioning in
these ﬁndings.438
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Immune mediated demyelinating disease after allogeneic
stem cell transplantation is a rare entity with unclear etiol-
ogy. Acute inﬂammatory demyelinating polyneuropathy
(AIDP) has been reported post related and unrelated alloge-
neic stem cell transplantation but no such case has been
reported post unrelated cord blood transplantation. Wehereby present the ﬁrst case of GBS post double umbilical
cord blood transplantation (DUCBT).
A 55 year old male with relapsed refractory CLL received
DUCBT with two 5/6 matched cord units, with ﬂudarabine,
cytoxan and total body irradiation based intensity condi-
tioning regimen. GVHD prophylaxis was with cyclosporine
and mycophenolate. Patient developed grade 4 acute GVHD
of the gut with a complete resolution with steroid therapy. 7
months post transplantation, patient presented with skin
rash and tingling in both feet that progressed rapidly to
lower extremity paralysis over the course of 2 days. Physical
exam showed maculo-papular rash affecting his upper ex-
tremities, upper chest and back area. Neurologic exam was
signiﬁcant for motor weakness in lower extremities 2/5,
plantar ﬂexion and knee ﬂexion 3/5. He had loss of deep
tendon reﬂexes in both lower extremities (Achilles and
Patellar) and upper extremities (biceps and triceps). Workup
revealed normal blood counts, organ function, vitamin B12,
folate, TSH level, free cortisol. SPEP and immunﬁxation were
also normal. Magnetic resonance imaging of the CNS was
normal. Serology for Lyme disease, Epstein Bar virus (EBV),
syphilis, cytomegalo virus (CMV), Hepatitis, HIV, toxoplasma,
enterovirus and human herpes virus 6 was negative. Blood
tests for autoimmune markers including ANA, acetylcholine
esterase and volted calcium channel antibodies were normal.
A lumbar puncture showed high protein level of 67mg/dl, 1
nucleated cell/mm3 and normal glucose. CSF was negative
for oligoclonal bands, West Nile virus, cryptosporidium,
HHV6, HSV 1 and 2, gram stain and cultures. Nerve con-
duction studies and needle electormyegraphy were sugges-
tive of AIDP.
Based on the above workup, he was diagnosed with GBS and
started on therapy with intravenous immunoglobulin at
0.5gm/kg for 4 days and prednisone 1mg/kg daily for the
treatment of GVHD. Etiology of GBS was presumed to be
related to GVHD as his workup was negative for campylo-
bacter, HIV and CMV. He became ambulatory without assis-
tance in 4 weeks but his weakness symptoms relapsed with
prednisone was taper. Prednisone was increased again to
1mg/kg and sirolimus was started. Patient was successfully
tapered of prednisone and remains fully ambulatory without
assistance or evidence of GVHD on single agent sirolimus 16
months post DUCBT.
This is the ﬁrst case of autoimmune demyelinating poly-
neuropathy post DUCBT with association of GVHD that was
managed successfully with a combination of intravenous
immunoglobulins, steroids and sirolimus.439
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Rapamycin inhibits mTOR, a crucial immune regulator.
RAPA-conditioned DC (RAPA-DC) enrich for Treg and induce
alloreactive T cell apoptosis. They promote experimental
allograft survival, yet secrete increased IL-12, crucial for
generation of IFN-g+CD4+ T cells. IFN-g is also pro-apoptotic
and IL-12-driven IFN-g inhibits GVHD. We hypothesized that
IL-12hi RAPA-DCwould facilitate IFN-g-mediated alloreactive
Table
IL-12hi RAPA-DC induce increased production of IFN-g by CD4þ T cells and
increased expression of Fas and caspase 8.
DC %CD4+IFNg+ %CD4+Fas+ %CD4+ Cleaved
caspase 8+
d 1 d 2 d 1 d 2 d 1 d2
CTR 3.20.8 3.62.1 1.30.6 1.91.5 9.24.7 6.23.9
CTR-LPS 6.11.2 6.03.1 3.51.0 3.11.6 10.64.0 8.74.2
RAPA 10.60.9* 10.55.9* 3.30.8* 4.11.5* 14.25.3* 11.45.6*
RAPA-LPS 10.62.1* 10.13.4* 7.11.4* 6.62.4 14.22.4 10.96.6
*p<0.05 compared to CTR
*denotes p<0.05 compared to untreated GVHD
1Median survival
Figure 2. Apoptosis induced by IL-12hi RAPA-DC is dependent on T cell but not
DC responses to IFN-g and on IL-12 expression.
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suppress GVHD.
DC were generated from wt, IFN-g-receptor (R)-/-, or IL-
12p40-/- C57BL/6 or BALB/c BM in 7 d culture  RAPA (10 ng/
ml). After LPS (100 ng/ml) or no stimulation for 18 h DC were
co-cultured with allogeneic CD4+ T cells in 5 d MLR  anti-
IFN-g Ab. T cells were examined by ﬂow for apoptosis
(Annexin V+7-AAD+), CD4 and Fas [CD95], and intracellular
IFN-g and cleaved caspase 8. Capacity of syngeneic DC to
prevent GVHD was assessed in irradiated BALB/c mice
reconstituted with 5x106 T cell-depleted B6 BM on d0. Re-
cipients received 106 BALB/c DC and 106 B6 T cells on d1.
Compared to CTR-DC, RAPA-DC enhanced T cell apoptosis
(12.72.3% vs 7.30.4%; +LPS: 28.54.4% vs 15.42.9%;
p<0.05). Neutralization of IFN-g in LPS-treated RAPA-DC
cultures decreased apoptosis to that of LPS-treated CTR-DC
(18.71.0% vs 15.42.9%; NS). Both RAPA-DC groups increased
IFN-g production by T cells compared to CTR (Table). IFN-g-
R-/- T cells exposed to LPS-stim RAPA-DC showed decreased
apoptosis compared to wt T cells (15.63.6% vs 4.91.1%;
p<0.05) (Fig 1). DC responses to IFN-g did not mediate the
function of RAPA-DC (12.47.6% [IFN-g-R-/- DC] vs 10.57.6%
[wt]; +LPS: 27.211.9% vs 30.116.3%; NS). LPS-stim IL-
12p40-/- RAPA-DC induced lower levels of apoptosis
compared to wt DC (16.98.9% vs 20.810.0%; p<0.05),
which was further reduced with anti-IFN-g (12.06.1%;
p<0.05). Compared to LPS-stim CTR-DC, IL-12hi RAPA-DC*denotes p<0.05
Figure 3. Autologous IL-12hi RAPA-DC signiﬁcantly prolong survival from acute GVHDincreased T cell Fas and cleaved caspase 8 (Table). Whereas
CTR-DC accelerated mortality from GVHD, LPS-treated RAPA-
DC signiﬁcantly prolonged survival (Fig 2).
Increased apoptosis of alloreactive T cells induced by LPS-
stim IL-12hi RAPA-DC is mediated via IFN-g and partly via
increased IL-12. Thus enhanced production of IL-12,
the principal inducer of IFN-g, may support the capacity of
RAPA-DC to prolong experimental allograft survival and
inhibit GVHD. IL-12hi human RAPA-DC, generated with.
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tation of both IL-12 and regulatory DC to suppress GVHD.440
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We have previously shown that inhibition of the MEK
pathway with selumetinib greatly reduced T cell prolifera-
tion induced by allo-DC stimulation with minimal loss in
virus-speciﬁc cytokine production in EBV and CMV-stimu-
lated T cells in vitro, and that selumetinib signiﬁcantly
reduced GVHD and increased survival in a GVHD mouse
model. Thus, MEK inhibitors represent a novel class of
immunosuppressive agents that potentially target GVHD
initiation while sparing beneﬁcial immunity in the allo-SCT
setting. We sought to determine if trametinib, a recently
FDA-approved MEK inhibitor based on clinical responses inFigure 1
Figure 2the melanoma setting, would also demonstrate selective
inhibition of alloreactivity while preserving virus-speciﬁc
immune function. In 6 allo-DC/responder PBMC pairs, we
assessed the dose response of inhibition of proliferation by
trametinib, and found similar dose response patterns to
selumetinib with w50% inhibition of alloreactivity at the 1
mM dose and nearly complete inhibition at 10 mM (Figure 1).
As previously reported with selumetinib, the percentage of
polyfunctional CMV and EBV-stimulated PBMC capable of
producing IL-2, IFN-g, TNF-a or MIP1-b was unchanged by
exposure to MEK inhibition (n¼4, CMV pp65 peptide re-
sponses shown in Figure 2). While the overall fraction of
functional responding cells to virus did not change in
response to MEK inhibition, TNF-a production was reduced
at higher doses of both trametinib and selumetinib. Further
experiments are planned, both in vitro and in animal models,
to conﬁrm the potential utility of this class of drugs to reduce
GVHD while preserving virus-speciﬁc T cell function in the
allo-SCT setting.441
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